Biblio
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting. Exp Hematol Oncol. 2023;12(1):57.
Baricitinib relieves DSS-induced ulcerative colitis in mice by suppressing the NF-κB and JAK2/STAT3 signalling pathways. Inflammopharmacology. 2024.
. Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting. Exp Hematol Oncol. 2024;13(1):17.